Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.

Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, Moyo S, Makhema J, Essex M, Lockman S.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):428-36. doi: 10.1097/QAI.0b013e31820bd2b6.

2.

Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.

Feiterna-Sperling C, Weizsaecker K, B├╝hrer C, Casteleyn S, Loui A, Schmitz T, Wahn V, Obladen M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):43-51.

PMID:
17356471
3.

Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.

Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, Thior I, Essex M.

AIDS. 2008 Aug 20;22(13):1633-40. doi: 10.1097/QAD.0b013e328307a029.

4.

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.

Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, Gilbert PB, Stevens L, Peter T, Kim S, van Widenfelt E, Moffat C, Ndase P, Arimi P, Kebaabetswe P, Mazonde P, Makhema J, McIntosh K, Novitsky V, Lee TH, Marlink R, Lagakos S, Essex M; Mashi Study Team.

JAMA. 2006 Aug 16;296(7):794-805.

PMID:
16905785
5.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
6.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
7.

Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.

Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, Leidner J, Makhema J, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8. doi: 10.1097/QAI.0b013e3181ffa4f5.

8.

Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.

Lehman DA, Chung MH, Mabuka JM, John-Stewart GC, Kiarie J, Kinuthia J, Overbaugh J.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):522-9. doi: 10.1097/QAI.0b013e3181aa8a22.

9.

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.

Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, Njiri F, John-Stewart GC.

Antivir Ther. 2008;13(6):799-807.

10.

Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine.

Baroncelli S, Pinnetti C, Genovese O, Tamburrini E, Floridia M.

J Med Virol. 2011 Mar;83(3):551-6. doi: 10.1002/jmv.21986.

PMID:
21264878
11.

Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV.

Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E, Bishop JB.

Environ Mol Mutagen. 2007 Apr-May;48(3-4):322-9.

12.

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study.

Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, Coombs RW, Scott G, Van Dyke RB, Shearer WT, Jimenez E, Diaz C, Harrison DD, Delfraissy JF.

AIDS. 1998 Oct 1;12(14):1805-13.

PMID:
9792381
13.

Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009.

Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C, Tookey PA; European Collaborative Study; National Study of HIV in Pregnancy Childhood.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):326-33. doi: 10.1097/QAI.0b013e31821d34d0. Erratum in: J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):e117.

14.

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, Lockman S, Fowler MG, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, Japour AJ.

AIDS. 2000 Feb 18;14(3):263-71.

PMID:
10716502
15.
16.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
17.

In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.

Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, Mandelbrot L, Delmas S, Lelong N, Khoshnood B, Warszawski J, Blanche S; French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial.

Clin Infect Dis. 2015 Jul 15;61(2):270-80. doi: 10.1093/cid/civ260. Epub 2015 Apr 1.

PMID:
25838291
18.

Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.

Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, Keapoletswe K, Tlale J, Modise TA, Asmelash A, Moyo S, van Widenfelt E, Makhema J, Essex M, Shapiro RL, Lockman S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):353-7. doi: 10.1097/QAI.0b013e31822d4063.

19.

Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.

Schwartz SR, Kumwenda N, Kumwenda J, Chen S, Mofenson LM, Taylor AW, Fowler MG, Taha TE.

Matern Child Health J. 2016 Mar;20(3):542-9. doi: 10.1007/s10995-015-1852-5.

20.

Supplemental Content

Support Center